12.30
+0.16(+1.32%)
Currency In USD
| Previous Close | 12.14 |
| Open | 12.1 |
| Day High | 12.44 |
| Day Low | 11.65 |
| 52-Week High | 17.15 |
| 52-Week Low | 9.7 |
| Volume | 115,818 |
| Average Volume | 231,560 |
| Market Cap | 322.84M |
| PE | -11.28 |
| EPS | -1.09 |
| Moving Average 50 Days | 13.04 |
| Moving Average 200 Days | 13.47 |
| Change | 0.16 |
If you invested $1000 in Benitec Biopharma Inc. (BNTC) 10 years ago, it would be worth $11.3 as of January 14, 2026 at a share price of $12.3. Whereas If you bought $1000 worth of Benitec Biopharma Inc. (BNTC) shares 5 years ago, it would be worth $198.23 as of January 14, 2026 at a share price of $12.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
GlobeNewswire Inc.
Jan 11, 2026 1:00 PM GMT
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and to
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
GlobeNewswire Inc.
Nov 06, 2025 5:19 AM GMT
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- di
Benitec Biopharma Inc. Announces Proposed Public Offering
GlobeNewswire Inc.
Nov 05, 2025 9:43 PM GMT
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- di